OBJECTIVE: To explore the association of the Pro12Ala mutation in the peroxisome proliferator-activated receptor g g g2 with severe obesity and the features of the metabolic syndrome in a population-based sample of Caucasians. PARTICIPANTS AND METHODS: The study is based on a case ± control design: 95 non-diabetic severely obese (body mass index, BMI b 35 kgam 2 ) cases and 280 normal weight (BMI`25 kgam 2 ), age-and sex-matched controls selected from the same population were studied. Height, weight, waist circumference, as well as blood pressure were measured according to a standard protocol. BMI at age 25 y was calculated on the basis of current height and reported weight at age 25 y Biochemical measurements included fasting glucose, triglycerides, high-density lipoprotein cholesterol and insulin. DNA analysis was conducted by PCR and gel electrophoresis. RESULTS: Age and gender distribution were similar in obese and normal weight participants. The percentage of people with the Pro12Ala mutation was not signi®cantly different in obese or normal weight participants (20% and 15%, respectively; P 0.32). Conversely, in obese participants with obesity starting in early adulthood (ie with BMI at age 25 above 26.9 kgam 2 which represents the median of the whole obese group), the Pro12Ala mutation was observed signi®cantly more frequently than in the normal weight controls (29% vs 15%; chi square 4.5, P`0.05; odds ratio 2.4; 95% CI 1.03 ± 5.36). No association of the Pro12Ala variant with any of the component of the metabolic syndrome measured in the study was observed in either obese, juvenile obese or normal weight participants. CONCLUSIONS: Results of this study indicate that the Pro12Ala mutation does not play a major role as a determinant of severe obesity andaor features of the metabolic syndrome in the general population. However, this mutation may be of greater importance as a contributor to early onset obesity.
Introduction
Obesity is a complex metabolic disorder associated with increased morbidity and mortality. 1 Several lines of evidence indicate that obesity has a genetic component, however, the genetic basis of obesity in the general population remains poorly understood. 1 ± 3 The nuclear peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate the expression of several genes involved in energy metabolism; in particular PPARg regulates adipocyte differentiation, lipid metabolism and intracellular insulin signalling, and is thus a promising candidate gene for several metabolic abnormalities, including obesity. 4 Recently Yen et al described a missense mutation of the PPARg gene involving a C ± G substitution at nucleotide 34, which results in the exchange of a proline for an alanine at position 12 of the PPARg2 protein. 5 This variant may be relevant to obesity and insulin resistance as the non-conservative amino acid substitution could cause signi®cant alteration in the protein conformation at the N-terminus domain, which has been shown to be involved in the ligandindependent transcriptional activity. 6 It is, therefore, conceivable that this PPARg2 variant affects weight regulation, insulin resistance andaor incidence of obesity; however, based on current knowledge, it is dif®cult to predict in which direction. One single study has explored the functional signi®cance of this mutation showing a lower in vitro transactivating capacity of the Pro12Ala variant and suggesting that this might lead to less ef®cient stimulation of PPARg target genes, thus predisposing to lower levels of adipose tissue accumulation. 7 The regulation of the transcriptional activity of the nuclear receptors in vivo is, however, very complex and involves several partners and modulating factors. Furthermore the studies which have so far investigated the association of the Pro12Ala variant with BMI have achieved con¯icting results: either a positive or a negative or no relation has been shown. 7 ± 11 Inconsistencies may be partly due to the heterogeneity of the populations studied, whose body mass index (BMI) ranges from lean to extremely obese; moreover some studies include population-based samples and others clinic-based samples.
Focusing on more homogeneous groups de®ned according to a more comprehensive phenotypic characterization may increase the probability of identifying true associations between genotypes and phenotypes. 12 Obesity results from a variable combination of genetic background with lifestyle predisposing to weight gain (ie high caloric intake and low energy expenditure). The relative impact of genetic background may vary in subclasses of obesity, being stronger in severe obesity, especially if developing in adolescence or early adulthood. 1 This work was therefore undertaken to assess whether the Pro12Ala mutation is associated: (a) with severe obesity; and (b) with clinical and metabolic markers of insulin resistance in a well-characterized population-based sample of Italian Caucasians. A second aim was to evaluate these associations in a subgroup of participants with severe obesity and weight gain already present in early adulthood.
Participants and methods
The study is conducted in Italian Caucasians and is based on a case ± control design. From a working population of 6000 telephone company employees aged 35 ± 59 y participating in a health screening, all those with BMI b 35 kgam 2 (ie class 2 and 3 obesity according to WHO) 13 were selected as cases. From the same population three normal weight (BMI`25 kga m 2 ), age-and sex-matched controls were randomly selected among those eligible. People with diabetes, de®ned as fasting glucose ! 126 mgadl, or reported use of medications for diabetes, 14 were excluded from the study. All together 95 unrelated, non-diabetic obese people (53 males and 42 females), and 280 normal weight controls (163 males and 117 females) were studied. With this sample size the study has an 80% power of detecting a relative risk of 2.1 or more for the presence of the Pro12Ala variant in obese vs normal weight people with a signi®cance of 0.05. The study protocol was approved by the local ethics committee. Informed consent was obtained from all participants.
Height and weight were measured in light underclothes according to a standard protocol. Blood pressure was measured in the supine position according to a standard protocol: three readings were taken and the average was used in the analysis. Reported weight at age 25 y was recorded; BMI at age 25 y was calculated on the basis of current height and reported body weight at age 25 y and used as a marker of weight gain occurring at a young age. Information on BMI at age 25 y was missing for 10 obese and 38 normal weight participants. To identify obesity subclasses, obese participants were strati®ed according to the median of BMI at age 25 y (ie above or below 26.9 kgam 2 ). Forty-one people in the obese group had BMI at age 25 y above the median; this condition will be referred to as severe obesity with early onset. All normal weight controls had BMI at age 25 y below 26.9 kgam 2 . Fasting glucose, triglycerides and highdensity lipoprotein (HDL)-cholesterol were measured on plasma by dry chemistry methods using an Ektachem DT-60 analyser (Eastman Kodak, Rochester, NY). 15 Plasma insulin was measured by radioimmunoassay 16 on frozen samples kept at 770 C for a maximum of 1 y. Genetic analysis was performed on frozen blood samples. DNA was extracted from peripheral leucocytes, ampli®ed by PCR and digested with the restriction endonuclease BstUI. The resulting fragments were separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining. 17 For 5% of the samples genetic analysis was performed in duplicate in a blinded fashion and a 100% concordance of results was obtained.
Statistical analysis
Data are given as meansAE standard deviation or percentages. An unpaired t-test was used to compare means. Insulin and triglycerides values were log transformed to correct for the skewness in the distribution; log transformed values were used in the analysis. The original values are given in the text and in the tables. For variables whose distribution could not be normalized by log transformation (ie BMI) non-parametric statistics were used. Proportions were compared by chi-square analysis. Odds ratios and 95% con®dence intervals were calculated by standard methods. 18 The statistical package of social sciences (SPSS) for Windows (version 7.5) was used for statistical analysis.
Results
Only two Pro12Ala homozygotes were found, one in the obese group and one in the normal weight group; in the analysis they were combined with the Pro12Ala heterozygotes and considered as the group`with mutation', which was compared with the Pro12 homozygotes indicated as the group`without mutation'.
The general characteristics of the obese and normal weight participants are given in Table 1 . The average BMI in the group with severe obesity was 37.7. Age and gender distribution were comparable in the two groups of severely obese and normal weight controls. The frequency of the Pro12Ala mutation was slightly, but not signi®cantly higher in the obese group (20% and 15%, respectively; chisquare 0.96, P 0.32), the odds ratio was 1.4 but the 95% con®dence interval included 1 (0.73 ± 2.6), as shown in Table 1 . By stratifying according to BMI at age 25 y (above or below 26.9 kgam 2 , ie the median of the whole obese group), a signi®cantly higher frequency of the Pro12Ala mutation was observed in the subgroup with severe obesity with early onset as compared to normal weight controls (29% vs 15%, chi-square 4.5, P`0.05). In this subgroup the odds ratio for the presence of the mutation was 2.4; the 95% con®dence interval is quite wide (1.03 ± 5.36) but does not include 1, thus supporting a signi®cantly increased risk of early onset obesity for individuals with this mutation as compared to those without. The Pro12Ala mutation was more common in men than in women, (21.7 vs 12.0, P`0.05). However the relation of the Ala variant with early onset obesity was the same in both genders (ie about twice as common in those with early onset obesity as compared to normoglycaemic controls (40.0% vs 19.6% and 18.2% vs 8.5%) in men and women, respectively).
By de®nition, BMI at age 25 y was signi®cantly higher in those with severe obesity with early onset compared with the entire group of severely obese (30.3 AE 3.9 vs 27.4 AE 4.6 kgam 2 ; P`0.001); however this subgroup did not differ from the total group of severely obese in terms of age, gender distribution and BMI measured at examination (Table 1) . Within each group (ie those with severe obesity, severe obesity with early onset and normal weight) no signi®cant differences in BMI were observed between those with or without the Ala mutation.
The main features of insulin resistance were also measured in the study. As expected they were more pronounced in the severely obese individuals as compared with the normal weight controls. In fact, obese participants had signi®cantly higher plasma insulin (79.2 AE 49.2 vs 39.0AE 13.8 pmolal, P`0.001), glucose (5.6AE 0.7 vs 5.3 AE 0.6, mmolal, P`0.001), triglycerides (1.78 AE 0.78 vs 1.34 AE 0.68 mmolal, P`0.001) and blood pressure (138AE 20 vs 133AE 17 mmHg, P`0.01; 89AE 15 vs 84AE 9.5 mmHg, P0
.01) and lower HDL cholesterol (1.2AE 0.3 vs 1.33AE 0.4 mmolal, P`0.01) than normal weight controls. In this respect participants with severe obesity with early onset did not differ from the total obese group. As for the Pro12Ala mutation, no signi®cant differences were observed in each of the components of the metabolic syndrome measured in the study between participants with or without the Pro12Ala variant. This holds true for the normal weight group, the group with severe obesity or severe obesity with early onset (Table 2 ).
Discussion
The results of this study indicate that the Pro12Ala mutation of the PPARg2 gene is not a major determinant of severe obesity in the general population. Furthermore, this variant is not associated with any of the features of insulin resistance measured in the study. The data, however, support a much stronger association of the mutation with a subclass of obesity (ie severe and with weight gain starting early in life). Differences in the frequency of the Pro12Ala mutation 
Previous studies have focused on the relation of the Pro12Ala variant with BMI showing either no association or a positive or an inverse association. In these studies the BMI of participants ranges from lean to very extreme obesity. Interestingly, the only study showing that the Pro12Ala mutation is positively associated with BMI was conducted in people with severe obesity (mean BMI 36.5 kgam 2 ). In this same study the ®nding could not be reproduced in a different population with less severe obesity (mean BMI 26.5 kgam 2 ), thus suggesting a potentially different role of the mutation in moderate or severe obesity. 8 Our study, conducted in a well-characterized group of people with severe obesity, contributes data which permit further clari®cation of the relation of the Pro12Ala variant with obesity. The sample size studied has an 80% power of detecting a relative risk of about 2 for the presence of the mutation in people with severe obesity as compared to normal weight controls. The study is clearly underpowered to detect a smaller contribution which, therefore, cannot be excluded and would be in line with the commonly held concept that obesity is multi-factorial with a polygenic background and a strong environmental component which may mask the small effect of many genes.
The signi®cantly higher frequency of the mutated gene in the smaller group of people with severe obesity with early onset, as compared with normal weight controls, suggests a more important role of the gene variant in this subclass of obesity. A stronger genetic impact in early onset obesity is plausible and is also in line with the existing knowledge of a higher heritability for early onset obesity as compared to obesity acquired later in life. 1 Restricting the analysis to a more homogeneous group based on a more comprehensive phenotypic characterization, increases the probability of detecting an association which could have been missed in the more heterogeneous group of all severely obese individuals. 12 This could also explain, at least in part, the con¯icting results reported to date; in fact, the proportion of this subclass of obesity may well differ in the various studies and, therefore, the association may be more or less diluted accordingly. In a previous study we could not ®nd an association of the Pro12Ala mutation with overweight in a population-based sample. 11 In agreement with the hypothesis that the Pro12Ala mutation plays a much stronger role in severe obesity with early onset, a very recent paper by Ek et al shows a signi®cant and positive association between the occurrence of the Pro12Ala mutation and BMI in people with severe obesity with juvenile onset, although in the condition of homozygosity. 19 As for insulin resistance we could not ®nd any association between insulin concentration, which is a marker of insulin resistance, and the Ala-mutated allele. This is in agreement with the majority of available information, although one study conducted with the use of the Bergman's model has reported lower insulin resistance in association with the Pro12Ala mutation, 7 and more recently Koch et al reported a better insulin sensitivity Ð evaluated by the glucose clamp technique Ð in ®ve obese offspring of type 2 diabetic patients with the Pro12Ala mutation as compared with those without. 20 Differences in the characteristics of study participants and methodology may well explain differences in results. Fasting insulin, although reported as a reasonably good marker of insulin resistance in non-diabetic people 21 is still less suitable than the clamp technique or Bergman's model to measure insulin sensitivity. In any case it seems unlikely that clinically relevant differences in insulin resistance occur in our study population between those with or without the mutation because, apart from insulin, none of the other components of the insulin resistance syndrome (ie triglycerides, HDL cholesterol, glucose and blood pressure) is different in the two groups.
The functional basis of ours as well as other authors' observations are not easy to explain on the basis of current knowledge, as the functional relevance of the Pro12Ala mutation in the PPARg2 is little explored. It has been reported that insulin enhances the ligand-independent transcriptional activity of PPARg2 through the AF1 domain in the Nterminus of the receptor. 6 The Pro12Ala mutation could make the receptor more susceptible to the insulin signalling by altering the protein structure. This effect might be related to modi®cations of the phosphorylation level of the receptor which, in turn, has been proved to in¯uence the transactivation potential of PPARg2. 22, 23 Thus, it is possible that the molecular variant under study results in increased adipogenesis and higher BMI in carrier individuals. This conclusion seems at odds with results of the only study which has so far investigated the functional signi®cance of the Pro12Ala mutation, 7 however in that in vitro model the interaction with insulin was not explored. Indeed recent data show a divergent modulating effect of the Pro12Ala variant on BMI in obese and lean Caucasian men. 19 This is compatible with the hypothesis that opposite effects of the Pro12Ala mutation on body weight regulation can be observed in conditions of low-normal insulin levels (as usually observed in lean individuals) or frank hyperinsulinaemia (as usually observed in severe obesity).
In conclusion, our study expands knowledge on the possible role of PPARg2 in obesity by establishing in a suf®ciently large population-based sample of severely obese individuals that the Pro12Ala mutation is not a major determinant of severe obesity as such, while it plays a more important role in a speci®c subclass of obesity, ie severe and with early onset.
